Previous 10 | Next 10 |
Seventy-Five Percent of All Cohort 4 Patients Have Experienced BCVA Increases Visual Acuity Continues to Decline in the Majority of Untreated Eyes No Acute or Delayed Inflammation or Rejection of OpRegen Observed, Even in Patients Treated with a Reduced Immunosuppres...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Benzinga Global Biotech...
Image source: The Motley Fool. Lineage Cell Therapeutics, Inc. (NYSEMKT: LCTX) Q4 2020 Earnings Call Mar 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Lineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Ca...
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants Ioana Hone – Director-Investor Relations Brian Culley – Chief Executive Officer Brandi Roberts – Chief Financial Officer Conference Call Participants Joe...
Lineage Cell Therapeutics (LCTX): Q4 GAAP EPS of -$0.01 beats by $0.03.Revenue of $0.4M (-67.7% Y/Y) misses by $0.28M.Cash, cash equivalents, and marketable securities of $41.6M Shares +0.5% AH.Press Release For further details see: Lineage Cell Therapeutics EPS beats by $0.03, mis...
Completed Enrollment in Phase 1/2a Clinical Trial of OpRegen for the Treatment of Dry Age-Related Macular Degeneration Announced First Known Report of Human Retinal Tissue Restoration; Persisted to 23 Months with Improved Vision Made Significant Improvements to OPC1 ...
Companhia Brasileira de Distribuicao (CBD) -76%.Soleno Therapeutics (SLNO) -26% after providing update on DCCR for the treatment of Prader-Willi syndromeSify Technologies (SIFY) -15%.Luokung Technology (LKCO) -15% after receipt of Nasdaq notification letter and a request for emergen...
Lineage Cell Therapeutics (LCTX) trades 7% down premarket after raising $11M in new capital from sales of its holdings of marketable securities, including shares of OncoCyte and Hadasit Bio-Holdings; also $25M in gross proceeds from its at-the-market offering.Lineage expects its ~$57M of...
Improved Cash Position Expected to Fund Operations for More Than Two Years Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that it raised $...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2020 financial and operating results on Thursday,...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...